Medical Manager

Dr. Karen Briley-Saebo, pHD

ablnbo@r.postjobfree.com

EMPLOYMENT AND APPOINTMENTS

Academic Appointments

****-****: Director. Cell Tracking Core Facility with the Translational

Molecular Imaging Institute (TMII), Department of Radiology, Mount Sinai

School of Medicine, New York.

. The function of this core was to design novel probes and methods to

allow for the longitudinal in vivo tracking of a variety of cells

including, antigen primed stem cells, dendritic cells, macrophages and

Tcells.

2009-2012: Assistant Professor

Institute (TMII), Department of Radiology, Mount Sinai School of Medicine,

New York.

. Lead an effort to translate novel nanoparticles targeted to oxidation

specific epitopes (OSE) for the in vivo detection of high risk

atherosclerotic plaque. We constructed a variety of multimodal

particles that enabled in vivo detection using diagnostic methods

including SPECT, PET and MRI. Additionally, evaluated the therapeutic

potential of these novel compounds and investigated other disease

processes where OSE played a critical role.

2007-2009: Instructor. Department of Radiology and Gene and Molecular

Medicine. Mount Sinai School of Medicine, New York.

. Worked on the development of novel MR pulse sequence to allow for more

accurate in vivo detection and quantification of iron oxide based

contrast agents. Additionally, I lead a team to further identify and

isolate viable cellular markers associated with unstable

atherosclerotic plaque. This work lead to a submission of a NIH grant

that was subsequently funded.

2005-2007: Post Doctoral Fellow. Department of Radiology, Imaging Science

Laboratory, Mount Sinai Medical School, New York.

. As post doctoral fellow I worked for Dr. Zahi Fayad in the Imaging

Science Laboratory. Responsibilities included the synthesis,

characterization, and in vivo efficacy testing of novel molecular

imaging probes for the detection of vulnerable atherosclerotic plaque

by MRI and PET/CT imaging. The materials developed included novel

lipid based probes containing targeting vectors (antibodies or

peptides) and MR/PET active labels. Characterization involved not only

physical and chemical characterization but also binding efficacy, ex

vivo cell studies, pharmacokinetics and biodistribution. In vivo

imaging was performed using mouse and rabbit models of

atherosclerosis. Confocal microscopy and immunohistology were used to

verify the presence of the probes within the arterial wall and to

correlate histological markers of vulnerability with the MR/PET

signal.

Industry

1989-2004: Research Scientist. GE Health Care (formerly Amersham/Nycomed),

Department of Pre-Clinical Efficacy Testing, Oslo, Norway.

. Manager of the MR/Imaging laboratory. Responsibilities included the

design and implementation of animal models for the evaluation of new

MR contrast agents. Models used relaxometry, MR imaging, ICP and

histology to evaluate the MR efficacy, bio-distribution and

pharmacokinetics of new contrast agents. I was also involved in

exploratory work to generate novel contrast agents and methods. This

effort resulted in the filing of 6 patents. In addition, I also

supported clinical and regulatory departments by supplying primary

pharmacology (efficacy) documentation for IND submission and

scientific consultation during Phase I and Phase II clinical studies.

EDUCATION

1987. Bachelor of Science in Chemistry, Ohio State University, Columbus,

Ohio.

2004. PhD in Diagnostic Radiology, Faculty of Medicine, Uppsala

University, Uppsala, Sweden. Thesis: Degradation, Metabolism and

Relaxation Properties of Iron Oxide Particles for Magnetic

Resonance Imaging.

TRAINING

1992 GLP/GMP certified (David Begg, Oslo, Norway).

1996. Courses in Surface and Colloidal Chemistry, Institute for

Surface Chemistry (Ytkemiska Institutet), Stockholm, Sweden.

1997. EU certification in Laboratory Animal Science (Category C

qualified), Norwegian college of veterinary medicine, Oslo,

Norway.

2002 Relaxation Theory and MR physics. Trained by Dr. Robert Muller,

University of Mons, Belgium.

2003. GCP certification, Uppsala, Sweden.

2004 Post Doctoral Training at Mount Sinai School of Medicine under

the mentorship of Zahi A. Fayad.

HONORS/AWARDS/PATENTS

HONORS:

. Distinguished service award from Magnetic Resonance in Medicine, 2011.

. Siemens Competition Mentor Award, 2009.

. Cited in Marquis Who's Who in America, 2008-2010.

. Best Poster Award, Society of Molecular Imaging, Cologne, Germany,

2005.

PATENTS:

. WO 98/10797. Title: External Calibration standards for MRI.

. NIDN 10403. Title: Use of MRA agents to evaluate both renal

function and morphology.

. PCT GB00/01963. Title: Use of MRA agents during induced passive

catheter tracking.

. WO 00/19227. Title: Use of USPIOs to determine in vivo blood

oxygenation levels.

. A61B/2002 6287. Title: Sodium shift agents for magnetic resonance

spectroscopy.

. WO 2004/054623. Title: Magnetic Resonance Imaging method and

compounds for use in methods (cardiac perfusion).

. SD2007-262 (provisional patent). Title: nanoparticles targeted to

oxidized low density lipoproteins.

OTHER PROFESSIONAL APPOINTMENTS

Editorial Boards:

Reviewer for:

Magnetic Resonance in Medicine

Investigative Radiology

MENTORING

I actively mentored one medical student enrolled in the PhD program at

Mount Sinai. In addition to this student, I also mentor several local High

School students enrolled in Science Research. By doing this I was able to

give back to the community and inspire students to peruse careers in

medical research. From the summer of 2006 to date I have mentored a total

of 16 students. Two students have received 2cnd place in the National

Siemens Competition in 2009 -2010.

PUBLICATIONS

1- Briley-Saebo KC, Nguyen TH, Saeboe AM, Cho YS, Ryu SK, Volkava E,

Dickson S, Leibundgut G, Weisner P, Green S, Casanada F, Miller YI, Shaw

W, Witztum JL, Fayad ZA, Tsimikas S. In vivo detection of oxidation-

specific epitopes in atherosclerotic lesions using biocompatible

manganese molecular magnetic imaging probes. J Am Coll Cardiol. 2012 Feb

7;59(6):616-26.

2- Briley-Saebo KC, Cho YS, Tsimikas S. Imaging of Oxidation-Specific

Epitopes in atherosclerosis and Macrophage-Rich Vulnerable Plaques. Curr

Cardiovasc Imaging Rep. 2011 Feb;4(1):4-16.

3- Cormode DP, Skajaa GO, Delshad A, Parker N, Jarzyna PA, Calcagno C,

Galper MW, Skajaa T, Briley-Saebo KC, Bell HM, Gordon RE, Fayad ZA, Woo

SL, Mulder WJ. A versatile and tunable coating strategy allows control of

nanocrystal delivery to cell types in the liver. Bioconjug Chem. 2011 Mar

16;22(3):353-61.

4- Briley-Saebo KC, Cho YS, Shaw PX, Ryu SK, Mani V, Dickson S, Izadmehr E,

Green S, Fayad ZA, Tsimikas S. Targeted iron oxide particles for in vivo

magnetic resonance detection of atherosclerotic lesions with antibodies

directed to oxidation-specific epitopes. J Am Coll Cardiol. 2011 Jan

18;57(3):337-47.

5- Briley-Saebo KC, Leboeuf M, Dickson S, Mani V, Fayad ZA, Palucka AK,

Banchereau J, Merad M Longitudinal tracking of human dendritic cells in

murine models using magnetic resonance imaging. Magn Reson Med. 2010

Nov;64(5):1510-9.

6- Adler ED, Chen VC, Bystrup A, Kaplan AD, Giovannone S, Briley-Saebo K,

Young W, Kattman S, Mani V, Laflamme M, Zhu WZ, Fayad Z, Keller G. The

cardiomyocyte lineage is critical for optimization of stem cell therapy

in a mouse model of myocardial infarction. FASEB J. 2010 Apr;24(4):1073-

81.

7- Leung K. Anti-malondialdehyde-modified low-density lipoprotein MDA2

monoclonal antibody gadolinium-labeled micelles. Molecular Imaging and

Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National

Center for Biotechnology Information (US); 2004-2010. 2009 Aug 15.

8- Cormode DP, Frias JC, Ma Y, Chen W, Skajaa T, Briley-Saebo K, Barazza A,

Williams KJ, Mulder WJ, Fayad ZA, Fisher EA. HDL as a contrast agent for

medical imaging. Clin Lipidol. 2009 Aug;4(4):493-500.

9- Beilvert A, Cormode DP, Chaubet F, Briley-Saebo KC, Mani V, Mulder WJ,

Vucic E, Toussaint JF, Letourneur D, Fayad ZA. Tyrosine polyethylene

glycol (PEG)-micelle magnetic resonance contrast agent for the detection

of lipid rich areas in atherosclerotic plaque. Magn Reson Med. 2009

Nov;62(5):1195-201.

10- Adler ED, Bystrup A, Briley-Saebo KC, Mani V, Young W, Giovanonne S,

Altman P, Kattman SJ, Frank JA, Weinmann HJ, Keller GM, Fayad ZA. In vivo

detection of embryonic stem cell-derived cardiovascular progenitor cells

using Cy3-labeled Gadofluorine M in murine myocardium. JACC Cardiovasc

Imaging. 2009 Sep;2(9):1114-22.

11- Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic

resonance imaging for atherosclerosis therapeutic evaluation: still

"rusty?" J Am Coll Cardiol. 2009 Jun 2;53(22):2051-2.

12- Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D,

Abbate A, Aguinaldo JG, Massey D, Fuster V, Vetrovec GW, Fayad ZA.

Macrophage-specific lipid-based nanoparticles improve cardiac magnetic

resonance detection and characterization of human atherosclerosis. JACC

Cardiovasc Imaging. 2009 May;2(5):637-47.

13- Cormode DP, Chandrasekar R, Delshad A, Briley-Saebo KC, Calcagno C,

Barazza A, Mulder WJ, Fisher EA, Fayad ZA. Comparison of Synthetic High

Density Lipoprotein (HDL) Contrast Agents for MR Imaging of

Atherosclerosis. Bioconjug Chem. 2009 Apr 20.

14- Briley-Saebo KC, Geninatti-Crich S, Cormode DP, Barazza A, Mulder WJ,

Chen W, Giovenzana GB, Fisher EA, Aime S, Fayad ZA. High-relaxivity

gadolinium-modified high-density lipoproteins as magnetic resonance

imaging contrast agents. J Phys Chem B. 2009 May 7;113(18):6283-9.

15- Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC,

Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived

lipopeptide in high-density lipoprotein MRI contrast agents for enhanced

imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging.

2008 Nov;3(6):233-42.

16- Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y,

Fisher EA, Fayad ZA. An ApoA-I mimetic peptide high-density-lipoprotein-

based MRI contrast agent for atherosclerotic plaque composition

detection. Small. 2008 Sep;4(9):1437-44.

17- Lipinski MJ, Briley-Saebo KC, Mani V, Fayad ZA. "Positive contrast"

inversion-recovery with ON[corrected]-resonant water suppression magnetic

resonance imaging: a change for the better? J Am Coll Cardiol. 2008 Aug

5;52(6):492-4.

18- Mani V, Adler E, Briley-Saebo KC, Bystrup A, Fuster V, Keller G, Fayad

ZA. Serial in vivo positive contrast MRI of iron oxide-labeled embryonic

stem cell-derived cardiac precursor cells in a mouse model of myocardial

infarction. Magn Reson Med. 2008 Jul;60(1):73-81.

19- Briley-Saebo KC, Shaw PX, Mulder W, Choi SH, Vucic E, Aguinaldo JG,

Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging

atherosclerotic lesions with Magnetic Resonance using antibodies that

recognize oxidation-specific epitopes. Circulation 2008 Jun

24;117(25):3206-15.

20- Mani V, Adler E, Briley-Saebo KC, Bystrup A, Fuster V, Keller G, Fayad

ZA. Serial in vivo positive contrast MRI of iron oxide-labeled embryonic

stem cell-derived cardiac precursor cells in a mouse model of myocardial

infarction. Magn Reson Med. 2008 Jun 25;60(1):73-81.

21- Calcagno C, Cornily JC, Hyafil F, Rudd JHF, Briley-Saebo KC, Mani V,

Goldschlager G, Machac J, Fuster V, Fayad ZA. Detection of Neovessels in

Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI

and 18F-FDG PET. Arterioscler Thromb Vasc Biol. 2008 May 8 (E-pub, a head

of print).

22- Briley-Saebo KC, Mani V, Hyafil F, Fayad ZA. Fractionated Feridex and

Positive Contrast: In vivo MR imaging of Atherosclerosis. Magn Reson Med

2008: 59(4):721-730.

23- Mani V, Adler E, Briley-Saebo KC, Bystrup A, Fuster V, Keller G, Fayad

ZA. Serial in vivo positive contrast MRI of iron oxide-labeled embryonic

stem cell-derived cardiac precursor cells in a mouse model of myocardial

infarction. Magn Reson Med. 2008 Jun 25;60(1):73-81.

24- Cornily JC, Hyafil F, Calcagno C, Briley-Saebo KC, Tunstead J,

Aguinaldo JG, Mani V, Lorusso V, Cavagna FM, Fayad ZA. Evaluation of

neovessels in atherosclerotic plaques of rabbits using an albumin-binding

intravascular contrast agent and MRI. J Magn Reson Imaging. 2008

Jun;27(6):1406-11

25- Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aquinaldo JG, Vucic

E, Amirbekian V, Tang C, Chin PT, Nicolay K, Fayad ZA. Molecular imaging

of macrophages in atherosclerotic plaques using bimodal PEG-micelles.

Magn Reson Med 2007 Dec;58(6):1164-70.

26- Amirbekian A, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo

JGS, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad

ZA. Detecting and assessing macrophages in vivo to evaluate

atherosclerosis noninvasively using molecular MRI. PNAS 2007 Jan

16;104(3):961-966.

27- Lipinski MJ, Frias JC, Amirbekian A, Mani V, Briley-Saebo KC, Sandberg

D, Massey D, Fuster V, Vetrovec G W, Fayad Z A. Improved ex-vivo MR

imaging of human aortic atherosclerosis with macrophage-specific

immunomicelles. JACC 2007; 49(9):405a.

28- Briley-Saebo KC, Amirbekian V, Mani V, Aguinaldo JG, Vucic E, Carpenter

D, Amirbekian S, Fayad ZA. Gadolinium mixed-micelles: effect of the

amphiphile on in vitro and in vivo efficacy in apolipoprotein E knockout

mouse models of atherosclerosis. Magn Reson Med 2006 Dec;56(6):1336-46.

29- Mani V, Briley-Saebo KC, Hyafil F, Fayad ZA. Feasibility of in vivo

identification of endogenous ferritin with positive contrast MRI in

rabbit carotid crush injury using GRASP. Magn Reson Med 2006

Nov;56(5):1096-106.

30- Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo

KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA. MRI to detect

atherosclerosis with gadolinium-containing immunomicelles targeting the

macrophage scavenger receptor.

Magn Reson Med 2006 Sep;56(3):601-10.

31- Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjornerud A,

Fayad ZA, Ahlstrom HK. Clearance of iron oxide particles in rat liver:

effect of hydrated particle size and coating material on liver

metabolism. Invest Radiol 2006 Jul;41(7):560-71.

32- Mani V, Briley-Saebo KC, Itskovich VV, Samber DD, Fayad ZA.Gradient

echo acquisition for superparamagnetic particles with positive contrast

(GRASP): sequence characterization in membrane and glass

superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 2006

Jan;55(1):126-35.

33- Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjornerud A,

Briley-Saebo K, Horsman MR, Ostergaard L. Intravascular contrast agent-

enhanced MRI measuring contrast clearance and tumor blood volume and the

effects of vascular modifiers in an experimental tumor. Int J Radiat

Oncol Biol Phys 2005 Mar 15;61(4):1208-15.

34- Briley-Saebo K, Hustvedt SO, Haldorsen A, Bjornerud A. Long-term

imaging effects in rat liver after a single injection of an iron oxide

nanoparticle based MR contrast agent. J Magn Reson Imaging 2004

Oct;20(4):622-31.

35- Briley-Saebo K, Bjornerud A, Grant D, Ahlstrom H, Berg T, Kindberg GM.

Hepatic cellular distribution and degradation of iron oxide nanoparticles

following single intravenous injection in rats: implications for magnetic

resonance imaging. Cell Tissue Res 2004 Jun;316(3):315-23.

36- Bjerner T, Johansson L, Wikstrom G, Ericsson A, Briley-Saebo KC,

Bjornerud A, Ahlstrom H. In and ex vivo MR evaluation of acute myocardial

ischemia in pigs by determining R1 in steady state after the

administration of the intravascular contrast agent NC100150 injection.

Invest Radiol 2004 Aug;39(8):479-86.

37- Eriksson R, Johansson L, Bjerner T, Briley-Saebo KC, Ahlstrom H. Uptake

of MnCl2 and mangafodipir trisodium in the myocardium: a magnetic

resonance imaging study in pigs. J Magn Reson Imaging 2004 May;19(5):564-

9.

38- Aumann S, Schoenberg SO, Just A, Briley-Saebo KC, Bjornerud A, Bock M,

Brix G. Quantification of renal perfusion using an intravascular contrast

agent (part 1): results in a canine model. Magn Reson Med 2003

Feb;49(2):276-87.

39- Koenig SH, Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Spiller M.

Three types of physical measurements needed to characterize iron oxide

nanoparticles for MRI and MRA: magnetization, relaxometry, and light

scattering. Acad Radiol 2002 May;9 Suppl 1:S5-10.

40- Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Bjornerod A, Spiller

M, Koenig SH. Important considerations in the design of iron oxide

nanoparticles as contrast agents for TI-weighted MRI and MRA. Acad Radiol

2002 May;9 Suppl 1:S34-7.

41- Bjornerud A, Johansson LO, Briley-Saebo K, Ahlstrom HK. Assessment of

T1 and T2* effects in vivo and ex vivo using iron oxide nanoparticles in

steady state--dependence on blood volume and water exchange. Magn Reson

Med 2002 Mar;47(3):461-71.

42- Bachmann R, Conrad R, Kreft B, Luzar O, Block W, Flacke S, Pauleit D,

Traber F, Gieseke J, Saebo K, Schild H. Evaluation of a new ultrasmall

superparamagnetic iron oxide contrast agent Clariscan, (NC100150) for MRI

of renal perfusion: experimental study in an animal model. J Magn Reson

Imaging 2002 Aug;16(2):190-5.

43- Bjornerud A, Briley-Saebo K, Johansson LO, Kellar KE. Effect of

NC100150 injection on the (1)H NMR linewidth of human whole blood ex

vivo: dependency on blood oxygen tension. Magn Reson Med 2000

Nov;44(5):803-7.

44- Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Bjornerud A, Spiller

M, Koenig SH. NC100150 Injection, a preparation of optimized iron oxide

nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging

2000 May;11(5):488-94.

45- Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Spiller M, Koenig SH.

'NC100150', a preparation of iron oxide nanoparticles ideal for positive-

contrast MR angiography. MAGMA 1999 Aug;8(3):207-13.

46- Rohl L, Ostergaard L, Simonsen CZ, Vestergaard-Poulsen P, Sorensen L,

Bjornerud A, Saebo KB, Gyldensted C. NC100150-enhanced 3D-SPGR MR

angiography of the common carotid artery in a pig vascular stenosis

model. Quantification of stenosis and dose optimization. Acta Radiol 1999

May;40(3):282-90.

47- Kellar KE, Briley-Saebo K. Phantom standards with temperature- and

field-independent relaxation rates for magnetic resonance imaging. Invest

Radiol 1998 Aug;33(8):472-9.

48- Toth E, Van Uffelen I, et al. (1998) A Gd-based linear polymer with

temperature independent proton relaxivities: a unique interplay between

water exchange and rotational contributions. Magn Reson Chem 1998

;36:S125-134.

49- Sjogren CE, Johansson C, Naevestad A, Sontum PC, Briley-Saebo K,

Fahlvik AK. Crystal size and properties of superparamagnetic iron oxide

(SPIO) particles. Magn Reson Imaging 1997;15(1):55-67.

50- Fossheim S, Saebo KB, Fahlvik AK, Rongved P, Klaveness J. Low molecular

weight lanthanide contrast agents: in vitro studies of mechanisms of

action. Magn Reson Imaging 1997 Jan-Feb;7(1):251-7.

51- Sjogren CE, Briley-Saebo KC, Hanson M, Johansson C. Magnetic

characterization of iron oxides for magnetic resonance imaging. Magn

Reson Med 1994 Mar;31(3):268-72.

OTHER PEER REVIEWED PUBLICATIONS

52- Briley-Saebo KC, Mulder WJ, Mani V, Hyfil F, Amibekian V, Aguinaldo JG,

Fisher EA, Fayad ZA. Magnetic resonance imaging of vulnerable

atherosclerotic plaques: current imaging strategies and molecular imaging

probes. Magn Reson Imaging 2007 Sep;26(3):460-79. Review.

Books and Book Chapters

Briley-Saebo KC, Book: Relaxation and Metabolism of Iron Oxide Based

Contrast Agents - Effect of the Physical and Chemical Properties of Iron

Oxide Based Contrast Agents on In-vivo Particle Degradation and MR Imaging

Efficacy. VDM Verlag Dr. M ller (2009-11-05). ISBN: 978-3-639-09816-7.

Zaim Wadghiri Y and Briley-Saebo KC: Chapter: Molecular Imaging.

Nanobiomaterials Handbook. CRC 1011 (in press). Editor Balaji Sitharaman

Briley-Saebo KC, Mulder WJ, Hyafin F, Mani V et al., Chapter 9: Molecular

Imaging of Atherosclerosis with MR in: Molecular and Cellular MR Imaging.

First Edition. CRC 2007 (editors Modo MMJ and Bulte JWM).

INVITED LECTURES/PRESENTATIONS

. Invited speaker at the International Society of Magnetic Resonance

Imaging in Medicine, 2011, Montreal, Canada.

. Invited speaker at National Institute of Health, Bethesda, Maryland, 9

March 2009.

. Invited speaker at the World Molecular Imaging Congress, Nice, France,

September 2008.

. Invited speaker at the Department of Radiology, New York University,

28 April 2008.

. Invited Speaker at the National Institute of Health, Bethesda,

Maryland, 10 April 2008.

. Invited speaker at the annual conference of the Society of

Cardiovascular Magnetic Resonance. Rome, Italy, February 2007.

. Invited speaker at the Ohio State University, Ohio, November 2006.

. Invited speaker at the GE Research Center, Schenectady, New York, July

2004.

. Invited speaker at the Department of Physics and Astronomy, University

of Wisconsin, Oshkosh, Wisconsin, February 1997.

Other Interests - Information: I am the proud mother of 3 and have a first

degree black belt in karate.

Contact Information: Address: 19 Autumn Ridge Ct, Katonah, NY 01536. Tel

home: 914-***-****

Contact this candidate